Pfizer-BioNTech make another application to provide existing vaccine to adolescents

Pfizer-BioNTech make another application to provide existing vaccine to adolescents

Pfizer-BioNTech make another application to provide existing vaccine to adolescents

Pfizer and its German partner BionTech's shot, also an mRNA vaccine like Moderna's, was the first vaccine to get a World Health Organization emergency use listing in the final hours of 2020. Some countries, including Britain, have recommended that only people over a certain age get the shot.

The figure depends upon a mix of the standard, two-dose vaccine administered to adults as well as potentially lower doses of booster shots and pediatric vaccines, should they be authorized, according to the company. Once the application is filed, an FDA advisory committee will publicly debate the evidence behind the shots before the agency decides whether to allow emergency use.

Soriot said the company did its best to deliver as much as it could to the European Union, and while he was disappointed it could not have delivered more, he was proud of the company's work on the vaccine and was "totally committed" to increasing supply.

Britain's medicine regulator on Thursday said there had been a further 41 reports of rare blood clots after doses of AstraZeneca's COVID-19 vaccine, but that the benefits of the shot continued to outweigh the risks for the majority of people.

As India gears up to launch its vaccine programme for 18-45-year-olds from May 01, a US Senator has urged the pharmaceutical companies to come forward and expand access to their vaccines in order to help India come out of the Covid crisis.

More than 3.1 million people worldwide have died of COVID-19, including more than 572,000 in the U.S. More than half of U.S. adults have received at least one dose of vaccine, and the government expects to have enough supply for the entire population by early summer.

Between procurement issues at the federal level, unreliable deliveries from the likes of Moderna, and delays related to changing guidance for AstraZeneca, things haven't been smooth. AstraZeneca has pledged that it will deliver the vaccine on a non-profit basis as long as the pandemic lasts.

A very small number of mainly frail, elderly COVID-19 patients are being hospitalised and dying even after having a first dose of Pfizer's or AstraZeneca's vaccines, but this does not mean the shots aren't working, United Kingdom researchers said on Friday.

The vaccine was developed by researchers at Oxford University, who licensed the technology to AstraZeneca in an effort to tap into the company's global manufacturing and distribution capacity.

Related news



[an error occurred while processing the directive]